Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
about
Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution.Antibiotics and extracorporeal circulation--one size does not fit allDynamic changes of microbial flora and therapeutic consequences in persistent peritonitis.Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics.A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill PatientsMechanisms of antimicrobial resistance in Gram-negative bacilli.Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearancePopulation pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?Potentially modifiable factors contributing to sepsis-associated encephalopathy.A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.Clinical Outcomes With Continuous Nafcillin Infusions in Children.Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis.Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting.The research agenda in VAP/HAP: next steps.UPLC-MS/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units.Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.Focus on adequate antimicrobial treatment and de-escalation in the ICU.[Antibiotic stewardship : Measures for optimizing prescription of anti-infective agents].Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU.Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?Antibiotic Dosing in Sustained Low-Efficiency Dialysis in Critically Ill PatientsPharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
P2860
Q30854769-892D5FD8-8DA0-4326-AC3C-0BE23FD59A7AQ35091940-2258612D-A10C-4536-BCC5-A95B367FB3D0Q35162610-89A9EDF2-689B-4F50-9EAA-138676E85C0CQ35816268-AC8FEA9A-D4FA-4607-8139-669114899A39Q35860038-3B2AB54D-BF69-47EC-80FE-8B1110FEC9C3Q35935319-B87D0942-E1AA-4002-ABC8-86D402F5683CQ36089167-81F9D0FE-B848-40E1-8BED-517D70660F5CQ36158212-EE3A1384-7DF6-4C76-876D-8B47B8B74515Q36438971-FD3CB2B0-BAA4-423B-998B-D5E404CE3FE4Q38369608-47777B6B-0716-44F8-9E4E-7D20DF918286Q38644824-D9F26373-E7E1-40BC-8A84-2BA900A85C08Q38705266-0D9F721E-9097-47C7-BE8D-D50A9328298EQ38798373-F72CB344-5251-45B9-8924-348ED3D13635Q39120027-537E1314-04C4-46D3-BFA2-BDD9E55AA02DQ39882067-1C7C75E2-D012-46EB-88B2-17C4531487DEQ40172540-DD6E25B2-75EB-4325-8125-D0F630962627Q40228714-681A4944-59D4-4DB5-99B6-0C831E0C7CD2Q40709270-7A84B117-C0CB-4E9F-92AF-4D17138C1F37Q41455375-B1E50C0E-EC2C-4AB0-8782-C8B2C0A9EBDDQ47442689-ADAE4962-321D-42A4-B22C-EED7AE7DF441Q47741687-4600DEF8-A305-4E28-AEBA-9E0003238F0AQ47974769-C3EEC411-6BA5-4299-BE3D-3A888F915FB0Q48016535-A50EE09A-7FCA-4761-9FC2-DCBD1B3A210CQ48139759-A096F276-8D45-42B2-81F2-0D1602573DA5Q48328989-26FFB455-ACB1-4FF7-B6C6-6EFA0F5D545DQ50128182-F531EA10-B245-404B-BBB7-1DF7B870820AQ53791273-3BE33956-921F-4DE9-8D3A-0FF6C8FAA24EQ54261873-E7180440-3619-444F-B816-6A5BF7A828E3Q57169898-A45B28D7-EA82-4357-8082-6E199C076DA0Q58701649-819E84FF-B298-48C6-8936-5027D7FD4BF3
P2860
Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Risk factors for target non-at ...... cs in critically ill patients.
@en
Risk factors for target non-at ...... cs in critically ill patients.
@nl
type
label
Risk factors for target non-at ...... cs in critically ill patients.
@en
Risk factors for target non-at ...... cs in critically ill patients.
@nl
prefLabel
Risk factors for target non-at ...... cs in critically ill patients.
@en
Risk factors for target non-at ...... cs in critically ill patients.
@nl
P2093
P2860
P50
P1476
Risk factors for target non-at ...... cs in critically ill patients.
@en
P2093
G Dimopoulos
Jan J De Waele
M Bassetti
M Kaukonen
P Montravers
S C Wallis
P2860
P2888
P304
P356
10.1007/S00134-014-3403-8
P577
2014-07-23T00:00:00Z